You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Systemic Therapy for Recurrent Epithelial Ovarian Cancer

Version: 4 ID: 4-3 Jul 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
J. Francis, N. Coakley, L. Elit, E.B. Kennedy, H. Mackay, The Gynecologic Cancer Disease Site Group

Guideline Objective

To recommend systemic therapy options for women with recurrent epithelial ovarian cancer including fallopian tube and primary peritoneal cancers.

Patient Population

The target population comprises women with recurrent epithelial ovarian cancer who have previously received platinum-based chemotherapy. Specific subgroups of interest are identified based on response to therapy.

Intended Guideline Users

The intended users of this guideline are gynecologic oncologists or medical oncologists in the province of Ontario.

Research Questions

What is the optimal systemic therapy for women with recurrent ovarian cancer who have previously received platinum-based chemotherapy?

Accordingly, the following comparisons were considered:

  • any systemic therapy option vs. another; and
  • any systemic therapy option vs. placebo.
pdf download Summary (PDF) (168.36 KB)
pdf download Full Report (PDF) (945.74 KB)